ESTRO35 Programme Book

MONDAY 2 MAY 2016

Symposium SBRT FOR OLIGOMETASTATIC DISEASE 08:45 - 10:00 | AUDITORIUM

The use of SBRT for oligometastatic disease is a developing clinical strategy that harnesses our greater understanding of disease biology and new technology. In this session, we will explore the complex tumour environment with attention to radiation related immuno-modulating mechanisms, its targets and abscopal effects. This session will review the current status, definitions and current evidence for the treatment of oligometastatic disease. Rationale and data will be presented for combination therapies, evaluating the aggressiveness of SBRT approaches, abdomino-pelvic examplers and the clinical deci- sion making process. Chair: V. Khoo (UK) Co-chair: V. Donato (Italy)

08:45 > Combining SBRT and immunotherapy: a promising approach? Speaker: F. Herrera (Switzerland)

SP-0405

09:10 > SBRT for metastatic disease: how far can and should we go? Speaker: M. Dahele (The Netherlands)

SP-0406

09:35 > Abdominal-pelvic targets

Speaker: M. Hoyer (Denmark)

SP-0407

Symposium HEAD AND NECK: STATE-OF-THE-ART AND DIRECTIONS FOR FUTURE RESEARCH 08:45 - 10:00 | GIALLA Chair: J. Bourhis (Switzerland) Co-chair: E.G. Russi (Italy)

08:45 > Molecular targeting with radiotherapy Speaker: K. Harrington (UK)

SP-0408

09:10 > Immunotherapy for HNSCC: an emerging paradigm? Speaker: J. Guigay (France)

SP-0409

09:35 > Proton therapy in HNSCC: better than IMRT? Speaker: C. Rasch (The Netherlands)

SP-0410

SCIENTIFIC PROGRAMME | PROGRAMME AND EXHIBITION GUIDE

123